T. Weinstock

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

D. Prais, P. Reix, H. Selvadurai, 2022, American journal of respiratory and critical care medicine.

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

R. Gibson, S. McColley, D. Waltz, 2021, American journal of respiratory and critical care medicine.

170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

K. Poplawska, E. Tullis, M. Chilvers, 2022, Journal of Cystic Fibrosis.

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.

G. Sahota, J. K. Bower, A. Elbert, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

M. Rosenfeld, S. McColley, B. Ramsey, 2023, American journal of respiratory and critical care medicine.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

S. McColley, D. Waltz, J. Davies, 2023, American journal of respiratory and critical care medicine.